Analysts Issue Forecasts for CRBU FY2030 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Analysts at Brookline Cap M issued their FY2030 earnings per share (EPS) estimates for shares of Caribou Biosciences in a research note issued to investors on Wednesday, February 4th. Brookline Cap M analyst L. Cann expects that the company will earn ($5.28) per share for the year. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share.

Other research analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, January 21st. HC Wainwright increased their price target on Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Truist Financial set a $7.00 price target on Caribou Biosciences in a report on Tuesday, November 4th. Finally, Citigroup upped their price objective on Caribou Biosciences from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Caribou Biosciences currently has a consensus rating of “Hold” and an average target price of $8.00.

Caribou Biosciences Stock Performance

CRBU opened at $1.57 on Friday. The stock has a market capitalization of $146.75 million, a price-to-earnings ratio of -0.92 and a beta of 2.61. The company has a fifty day moving average of $1.65 and a 200 day moving average of $1.94. Caribou Biosciences has a fifty-two week low of $0.66 and a fifty-two week high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.06. Caribou Biosciences had a negative net margin of 1,690.45% and a negative return on equity of 69.85%. The firm had revenue of $2.20 million for the quarter, compared to analysts’ expectations of $1.94 million.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Green Alpha Advisors LLC raised its stake in shares of Caribou Biosciences by 3.1% in the fourth quarter. Green Alpha Advisors LLC now owns 375,139 shares of the company’s stock valued at $596,000 after acquiring an additional 11,440 shares during the period. CWM LLC grew its holdings in Caribou Biosciences by 53.5% during the 2nd quarter. CWM LLC now owns 33,839 shares of the company’s stock valued at $43,000 after purchasing an additional 11,798 shares during the last quarter. R Squared Ltd bought a new position in Caribou Biosciences during the 3rd quarter valued at about $29,000. Bronte Capital Management Pty Ltd. bought a new stake in Caribou Biosciences in the fourth quarter worth about $25,000. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Caribou Biosciences by 69.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 40,813 shares of the company’s stock valued at $51,000 after buying an additional 16,736 shares during the period. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.